ArticleScience (New York, N.Y.)2024
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Open access · hybridAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.Nature medicine · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Immune activation during broadly neutralizing antibody-mediated HIV suppression prior to post-intervention control.bioRxiv : the preprint server for biology · 2026Article
- Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies.Cell reports. Medicine · 2026Article
- Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques.The Journal of clinical investigation · 2026Article
- Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.medRxiv : the preprint server for health sciences · 2026Article
- CD8Nature · 2026Article
- Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody.Antibodies (Basel, Switzerland) · 2026Article
- A Nonparametric Approach to Practical Identifiability of Nonlinear Mixed Effects Models.Bulletin of mathematical biology · 2026Article
- HIV-1 bNAb Vaccinal Effect-An Underachieving Goal?Current HIV research · 2026Review
- Searching for a HIV-1 Cure.Theranostics · 2026Review
- Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.medRxiv : the preprint server for health sciences · 2025Article
- CD8medRxiv : the preprint server for health sciences · 2025Article
- Monoclonal Antibodies (mAbs) and Proteins: The Biologic Drugs Approved by the Food and Drug Administration (FDA) in 2024.Biomedicines · 2025Review
- Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.Journal of virology · 2025Review
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children.Current opinion in HIV and AIDS · 2025Review
- SLAMF6 enables efficient attachment, synapse formation, and killing of HIV-1-infected CD4bioRxiv : the preprint server for biology · 2025Article
- SIV Env RhmAbs + N-803 at ART initiation prolongs viral decay without disrupting reservoir establishment in SIV-infected infant macaques.PLoS pathogens · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 11 institutions in 1 country.
So-Yon Lim *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-9654-2335
Jina Lee *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-2000-1417
Christa E OsunaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-2761-2456
Pratik VikheCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-1096-970X
Dane R SchalkWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0002-4865-827X
Elsa ChenCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Emily FrayDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-5850-6237
Mithra KumarDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-8361-7935
Nancy Schultz-DarkenWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0002-8436-2820
Eva RakaszWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0001-8197-5309
Saverio CapuanoWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ruby A LaddWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0003-2827-3249
Hwi Min GilWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0002-3722-4302
David T EvansWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0003-2498-6292
Emily K JengAltor Biosciences, Miramar, FL 33027, USA.
Michael SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-6444-3562
Malcolm MartinLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-1232-2966
Christiaan Van DorpLos Alamos National Laboratory, Los Alamos, NM 87545, USA.ORCID 0000-0002-7504-9947
Alan S PerelsonLos Alamos National Laboratory, Los Alamos, NM 87545, USA.ORCID 0000-0002-2455-0002
Hing C WongAltor Biosciences, Miramar, FL 33027, USA.
Janet D SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-6712-3775
Robert SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-1764-1993
Jeffrey T SafritImmunityBio, Culver City, CA 90232, USA.
Douglas F NixonDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-2801-1786
Patrick Soon-ShiongImmunityBio, Culver City, CA 90232, USA.ORCID 0000-0002-4682-8298
Michel NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-0592-8564
James B WhitneyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-3674-0193
University of Wisconsin–Madison · USBeth Israel Deaconess Medical Center · USJohns Hopkins University · USAltor BioScience (United States) · USHoward Hughes Medical Institute · USImmunityBio (United States) · USBoston College · USCornell University · USLos Alamos National Laboratory · USNational Institutes of Health · USSanta Fe Institute · US
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MWNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7MREACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9MBELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1MThe Biology of HIV InfectionsZIAAI001213 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARTIN, MALCOLM · 2016 to 2025
$23.7MViral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5MResource CoreP40OD028116 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2020 to 2026
$5.9MKIR and MHC Class I Immunogenetics in SIV InfectionR37AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2019 to 2026
$5.6MModeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0MHarnessing adaptive NK cell transfer to deplete viral reservoirsR01AI161816 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BARKER, EDWARD, EVANS, DAVID T · 2021 to 2025
$3.8MImmune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7MTLR Immunotherapy to Eradicate Anatomic SIV ReservoirsR01AI127089 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2016 to 2020
$3.5MNIAID NIH HHS P01 AI131365NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI127089NIAID NIH HHS R01 AI152703NIAID NIH HHS R01 AI155163NIAID NIH HHS R01 AI161816NIAID NIH HHS R37 AI028433NIAID NIH HHS R37 AI095098NIAID NIH HHS R56 AI091514NIAID NIH HHS R56 AI122942NIAID NIH HHS UM1 AI126617NIAID NIH HHS UM1 AI144462NIAID NIH HHS UM1 AI164565NIH HHS P40 OD028116NIH HHS P51 OD011106NIH HHS R01 OD011095
Abstract
The eradication of the viral reservoir represents the major obstacle to the development of a clinical cure for established HIV-1 infection. Here, we demonstrate that the administration of N-803 (brand name Anktiva) and broadly neutralizing antibodies (bNAbs) results in sustained viral control after discontinuation of antiretroviral therapy (ART) in simian-human AD8 (SHIV-AD8)-infected, ART-suppressed rhesus macaques. N-803+bNAbs treatment induced immune activation and transient viremia but only limited reductions in the SHIV reservoir. Upon ART discontinuation, viral rebound occurred in all animals, which was followed by durable control in approximately 70% of all N-803+bNAb-treated macaques. Viral control was correlated with the reprogramming of CD8
Indexed as
Anti-Retroviral AgentsRecombinant Fusion ProteinsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsBroadly Neutralizing AntibodiesCD8-Positive T-LymphocytesDrug Therapy, CombinationHumansImmunotherapyMacaca mulattaRemission InductionViral LoadALT-803Anti-Retroviral AgentsBroadly Neutralizing AntibodiesRecombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.